|
September 25, 2023
|
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
|
|
September 19, 2023
|
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
|
|
September 11, 2023
|
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
|
|
September 5, 2023
|
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
|
|
August 14, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
|
|
August 3, 2023
|
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
|
|
August 2, 2023
|
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
|
|
July 27, 2023
|
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
|
|
July 17, 2023
|
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
|
|
July 5, 2023
|
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
|
